A similar effect was seen with chronic dosing of optimized, long acting GLP-1 analogues liraglutide and semaglutide in patients with obesity (26, 27) or T2D (28, 29). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.